Analyses supporting phase 2 clinical trial dose selection for zabofloxacin in community-acquired pneumonia
Analyses supporting phase 2 clinical trial dose selection for zabofloxacin in community-acquired pneumonia, Lead author: Ambrose PG, presented at 18th annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), April 19 – 22, 2008, Barcelona, Spain